Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Astellas Pharma
Woman and Man Max 99 years
Astellas Pharma GmbH
Update Il y a 4 ans
A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF BASED IMMUNOSUPPRESSIVE REGIMEN
To assess the safety of a tacrolimus modified release, MR4, based immunosuppressive regimen in stable kidney transplant subjects converted on a 1:1 (mg : mg) basis from a Prograf based immunosuppress...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A RANDOMISED, DOUBLE-BLIND STUDY TO COMPARE THE EFFECT ON SYMPATHETIC ACTIVITY AND HEMODYNAMIC PROFILE OF BARNIDIPINE AND AMLODIPINE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION
To compare the effect of barnidipine and amlodipine on sympathetic activity by assessment of plasma norepinephrine levels in the forearm after 12 weeks of therapy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tamsulosin hydrochloride OCAS 0.4 mg monotherapy, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component
To assess the efficacy of fixed dose combinations of tamsulosin OCAS 0.4 mg and solifenacin (6 mg and 9 mg) in comparison with tamsulosin OCAS 0.4 mg monotherapy in male subjects with LUTS associated ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder
To assess the efficacy of YM178 50 mg qd and YM178 100 mg qd against placebo in the treatment of subjects with symptoms of overactive bladder.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A phase II, randomized, double-blind, parallel-group, placebo-controlled, 12-week treatment, adaptive proof-of-principle study of twice daily oral dosing of a novel PDE4 inhibitor (ASP9831) in subjects with non-alcoholic steatohepatitis (NASH)
Part 1: Objective: To explore exposure to ASP9831 in patients with Non-alcoholic Steatohepatitis (NASH) and to compare the data with healthy volunteer data Part 2: Primary objective: To study the ef...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF YM155 IN SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) PREVIOUSLY TREATED WITH AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
To evaluate the efficacy of YM155 based on the percentage of subjects that obtain a PSA response. PSA response is defined as a ≥ 50% reduction in PSA that is confirmed by a second PSA value 3 weeks a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Astellas Pharma
Update Il y a 4 ans
Astellas 155-CL-009 : Essai de phase 2 évaluant l’efficacité et la tolérance d’un traitement par YM155 chez des patients ayant un lymphome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de l’essai est d’évaluer l’efficacité et la tolérance d’un traitement par YM155 chez des patients ayant un lymphome.
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Man
Between 18 years
and 99 years
Astellas Pharma
Update Il y a 4 ans
Etude 9785-CL-0123 : étude de phase 2 d’extension visant à collecter des données de sécurité sur le long terme chez des patients ayant cancer de la prostate et ayant participé à une étude clinique testant un traitement par enzalutamide.
Le cancer de la prostate est le cancer masculin le plus fréquent. Plusieurs stratégies thérapeutiques existent dans la prise en charge de ce cancer, notamment la chimiothérapie qui consiste à administ...
Country
France
organs
Prostate
Specialty
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Astellas Pharma
Update Il y a 6 ans
Étude 2215-CL-0301 : étude de phase 3 randomisée comparant l’efficacité du ASP2215 (gilteritinib) à une chimiothérapie de rattrapage chez des patients ayant une leucémie myéloïde aiguë récurrente ou réfractoire avec une mutation FLT3.
La leucémie myéloïde aiguë résulte des mutations acquises dans l’ADN de cellule de la moelle osseuse en développement. Cette cellule devient leucémique et se multiplie de façon incontrôlable, donnant ...
Country
France
organs
Leucémies aiguës
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis Ensayo aleatorizado comparando placebo y ASP3652 en el tratamiento de mujeres con Sindrome de Dolor Vesical/ Cistitis intersticial
To investigate efficacy of ASP3652 in female subjects with BPS/IC Investigar la eficacia del ASP3652 en mujeres con SDV/CI
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next